3D Systems is expanding its development efforts focused on regenerative medicine and bioprinting solutions. This decision was driven by progress made in collaboration with United Therapeutics Corporation and its organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, on the development of 3D printing systems for solid-organ scaffolds.
Leveraging this work as well as accomplishments with additional partners, 3D Systems intends to invest, further develop, and commercialize solutions for the diverse application opportunities in regenerative medicine, including the development of non-solid organ applications requiring biologically sustainable vasculature.
In 2020, 3D Systems and United Therapeutics achieved significant progress in the development of a next-generation additive manufacturing platform solution for lung scaffolds that is capable of full size, vascularized, rapid, micron-level printing. 3D Systems’ capabilities as a technology innovator, spanning hardware, software, and materials science, combined with United Therapeutics’ expertise in regenerative medicine has enabled advances in lung modeling, 3D printing, as well as material formulation using a unique rhCollagen, and material handling to yield significant capabilities in bioprinters and biomaterials for lung manufacturing.
As a result, 3D Systems has built a portfolio of unique capabilities specifically designed to address the requirements of regenerative medicine applications. The newly developed Print to Perfusion™ process enables 3D printing of high-resolution scaffolds, which can be perfused with living cells to create tissues. The ability to print large, vascularized, highly detailed hydrogel scaffolds at rapid speeds opens new opportunities for a range of tissue applications.